Infrapyloric and Greater Curvature Lymph Node Metastasis in Colon Cancer

N/AActive Not RecruitingNCT03936530

Shanghai Minimally Invasive Surgery Center432 enrolled

Overview

The infrapyloric (No.206) and greater curvature (No.204) lymph node metastasis in adenocarcinoma located at hepatic flexure and right half of transverse colon has not been well discribed and analysed. The aim of this study is to assess the rate of this lymph node metastasis and to reveal its prognostic value for colon cancer located at hepatic flexure and right half of transverse colon. Meanwhile, we can evaluate the safety and feasibility of this extented lymphadenectomy in right hemi-colectomy.

Study Type

OBSERVATIONAL

Enrollment

432

Conditions

Colorectal Neoplasm

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age between 18 and 75 years * American Society of Anesthesiologists (ASA) score I to III * A biopsy proven histological diagnosis of colorectal carcinoma * tumor located at hepatic flexure and right half of transverse colon * Undergoing right hemi-colectomy with extented lymphadenectomy of infrapyloric (No.206) and greater curvature (No.204) lymph node * Preoperative staging cT2-4aN0M0 or cTanyN+M0 * Willing to participate and informed consent signed Exclusion Criteria: * Pregnant or lactating women * Synchronous colorectal carcinoma * History of colorectal cancer or other malignant tumors * Clinical evidence of metastasis * Preoperative staging cT1N0 or cT4bNany * Emergency procedure

Locations (1)

Ruijin hospital

Shanghai, Shanghai Municipality, China

Outcomes

Primary Outcomes

metastasis rate

metastasis rate of infrapyloric (No.206) and greater curvature (No.204) lymph node

Time frame: an average of 1 year

Secondary Outcomes

lymphadenectomy time

time of lymphadenectomy of infrapyloric (No.206) and greater curvature (No.204) lymph node

Time frame: an average of 1 year

intraoperative complication

Time frame: an average of 1 year

postoperative complication

Time frame: an average of 1 year

3-year DFS

3-year disease free survival

Time frame: an average of 3 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.